Anavex Life Sciences Corp (AVXL)

[JB3729]

Sounds like TauRX's drug lacks dose response -

TauRX's comcompounds had somewhat inconclusive and puzzling Phase 2, though it apparently still proceeded to Phase 3. There was statistical significance in efficacy for medium dosage but none at highest dosage, and not insignificant AE's.

On the other hand, robust dose response was part of the remarkable 2-73 five week data -

The dose-response results were robust to statistical resampling (bootstrap analysis x 10,000 resamples). Analysis of variance and post hoc tests as well as Bayesian hierarchal analysis further confirmed that the higher doses achieved a statistical significant improvement in the MMSE-? score over 5 weeks compared to the lower doses. Based on these findings, it was estimated that an oral dose of 30 mg ANAVEX 2-73 had approximately 80% probability of achieving a +2 points or higher improvement in MMSE score over 5 weeks of treatment. Doses in this range have thus far been well tolerated by the study’s subjects, with no adverse events reported above grade one.
http://www.anavex.com/?news=anavex-announces-positive-dose-response-data-for-anavex-2-73-in-alzheimers-disease-patients